Who
Elizabeth L. Hougen
Director
Company insider
Files Form 4 as: Director, Artiva Biotherapeutics; EVP, Finance & CFO, Ionis Pharmaceuticals.
In numbers
- Trades disclosed
- 276
- Buys
- 0
- Sells
- 40
- Bought
- $0
- Sold
- $49.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 2 Jan 2013
- Last trade
- 10 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,250 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,250 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 17 Mar 2026filed 18 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $745K10,172 at $73.21 | filing |
| 17 Mar 2026filed 18 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $745K10,172 at $73.21 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3.7M60,299 at $60.89 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —61,041 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —60,299 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3.5M61,041 at $56.78 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $1.1M33,118 at $32.60 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,118 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,541 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —61,041 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —60,299 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $772K20,541 at $37.58 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $14.9M205,608 at $72.38 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $687K9,440 at $72.77 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,118 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3.7M60,299 at $60.89 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Elizabeth L. Hougen; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.